Pretransplantation characteristics of patients
Patient no. . | Sex . | Age, y . | Type of MS . | EDSS . | Disease duration, mo . | Prior therapy . |
---|---|---|---|---|---|---|
1 | F | 34 | SP | 8.0 | 163 | IFN-1β, GA |
2 | F | 49 | SP | 6.5 | 277 | INF-1β, MPSE, bee stings |
3 | M | 37 | PP | 6.0 | 10 | MPSE |
4 | F | 46 | RR | 7.0 | 97 | IFN-α, IFN-1β, GA, MPSE |
5 | M | 35 | SP | 6.0 | 24 | IFN-1α, IFN1β, GA |
6 | F | 37 | SP | 6.0 | 69 | IFN-1α, IFN-1β, GA |
7 | F | 51 | SP | 7.0 | 69 | IFN-1β |
8 | F | 48 | SP | 8.0 | 79 | IFN-1β |
9 | F | 57 | SP | 7.0 | 82 | IFN-1α, IFN1β, GA |
10 | M | 51 | PP | 6.5 | 84 | IFN-α, IFN-1β, MPSE |
11 | F | 47 | SP | 8.0 | 107 | IFN-1α, IFN1β, GA |
12 | M | 38 | SP | 6.5 | 119 | IFN-1α, IFN1β |
13 | F | 29 | SP | 6.5 | 138 | IFN-α, IFN-1β, GA, MPSE |
14 | M | 43 | PP | 7.0 | 110 | IFN-1β |
15 | M | 27 | PP | 7.5 | 48 | IFN-1β, GA |
16 | M | 60 | SP | 7.5 | 50 | IFN-α, IFN-1β, MPSE |
17 | F | 44 | SP | 7.5 | 188 | IFN-α, GA, Ctx |
18 | F | 47 | SP | 7.5 | 149 | IFN-1β, Mtx |
19 | M | 29 | SP | 5.0 | 144 | IFN-α |
20 | M | 36 | PP | 6.5 | 48 | MPSE |
21 | M | 45 | SP | 8.0 | 83 | IFN-1β, GA |
22 | M | 44 | PP | 6.5 | 94 | IFN-α, IFN-1β, Imuran |
23 | M | 52 | PP | 5.0 | 49 | IFN-α |
24 | M | 28 | PP | 7.0 | 12 | IFN-α, IFN-1β, IVIG, Prd, Nv |
25 | F | 47 | SP | 8.0 | 179 | IFN-1β, Ctx, Prd |
26 | M | 41 | SP | 7.0 | 195 | IFN-α, IFN-1β, IVIG |
Median | 41 | 7.0 | 84 |
Patient no. . | Sex . | Age, y . | Type of MS . | EDSS . | Disease duration, mo . | Prior therapy . |
---|---|---|---|---|---|---|
1 | F | 34 | SP | 8.0 | 163 | IFN-1β, GA |
2 | F | 49 | SP | 6.5 | 277 | INF-1β, MPSE, bee stings |
3 | M | 37 | PP | 6.0 | 10 | MPSE |
4 | F | 46 | RR | 7.0 | 97 | IFN-α, IFN-1β, GA, MPSE |
5 | M | 35 | SP | 6.0 | 24 | IFN-1α, IFN1β, GA |
6 | F | 37 | SP | 6.0 | 69 | IFN-1α, IFN-1β, GA |
7 | F | 51 | SP | 7.0 | 69 | IFN-1β |
8 | F | 48 | SP | 8.0 | 79 | IFN-1β |
9 | F | 57 | SP | 7.0 | 82 | IFN-1α, IFN1β, GA |
10 | M | 51 | PP | 6.5 | 84 | IFN-α, IFN-1β, MPSE |
11 | F | 47 | SP | 8.0 | 107 | IFN-1α, IFN1β, GA |
12 | M | 38 | SP | 6.5 | 119 | IFN-1α, IFN1β |
13 | F | 29 | SP | 6.5 | 138 | IFN-α, IFN-1β, GA, MPSE |
14 | M | 43 | PP | 7.0 | 110 | IFN-1β |
15 | M | 27 | PP | 7.5 | 48 | IFN-1β, GA |
16 | M | 60 | SP | 7.5 | 50 | IFN-α, IFN-1β, MPSE |
17 | F | 44 | SP | 7.5 | 188 | IFN-α, GA, Ctx |
18 | F | 47 | SP | 7.5 | 149 | IFN-1β, Mtx |
19 | M | 29 | SP | 5.0 | 144 | IFN-α |
20 | M | 36 | PP | 6.5 | 48 | MPSE |
21 | M | 45 | SP | 8.0 | 83 | IFN-1β, GA |
22 | M | 44 | PP | 6.5 | 94 | IFN-α, IFN-1β, Imuran |
23 | M | 52 | PP | 5.0 | 49 | IFN-α |
24 | M | 28 | PP | 7.0 | 12 | IFN-α, IFN-1β, IVIG, Prd, Nv |
25 | F | 47 | SP | 8.0 | 179 | IFN-1β, Ctx, Prd |
26 | M | 41 | SP | 7.0 | 195 | IFN-α, IFN-1β, IVIG |
Median | 41 | 7.0 | 84 |
F indicates female; SP, secondary progressive; IFN-β interferon-β (Betaseron); GA, glatiramer acetate; MPSE, methylprednisolone; M, male; PP, primary progressive; RR, relapsing-remitting; IFN-α, interferon-α (Avonex); Ctx, cyclophosphamide; Mtx, methotrexate; IVIG, intravenous immunoglobulin; Prd, prednisone; and Nv, mitoxantrone.